IBD Dialogue Special Edition

IBD Dialogue – Treat To Target in IBD

What does “treat to target” mean to the clinician in 2016?

Richard N. Fedorak, MD

Volume 2 | Issue 1

What can we learn from the REACT study results?

Brian G. Feagan, MD

Volume 2 | Issue 2

What is the role of fecal calprotectin in monitoring in the treat-to-target strategy in IBD?

Smita Halder, MD

Volume 2 | Issue 3

What are the benefits and risks of the treat-to-target strategy in IBD?

John K. Marshall, MD

Volume 2 | Issue 4

What did STRIDE recommend about treat to target in IBD?

Mark S. Silverberg, MD

Volume 2 | Issue 5

How should patients be monitored for loss of response in the treat-to-target strategy?

Mark S. Silverberg, MD

Volume 2 | Issue 6

What is the role of transabdominal ultrasound in management of patients with IBD?

Kerri Novak, MD

Volume 2 | Issue 7

How useful is video capsule endoscopy in diagnosing and monitoring Crohn’s disease?

Ernest G. Seidman, MD

Volume 2 | Issue 8

What is the relation between extraintestinal manifestations and treatment choice in IBD?

A. Hillary Steinhart, MD

Volume 2 | Issue 9

How is shared decision-making evolving in IBD practice?

John K. Marshall, MD

Volume 2 | Issue 10

What does treat to target really mean in IBD?

Brendan Halloran, MD

Volume 2 | Issue 11

What is the importance of the treat-to-target strategy in pediatric patients with IBD?

Anne M. Griffiths, MD

Volume 2 | Issue 12

IBD Dialogue – Therapeutic Drug Monitoring in Clinical Practice

15 years of infliximab – From episodic treatment to therapeutic drug monitoring

John K. Marshall, MD

Volume 1 | Issue 1

Individual variability in infliximab excretion and elimination

Diane R. Mould, PhD

Volume 1 | Issue 2

How do the different TDM assays differ in clinical use?

Remo Panaccione, MD

Volume 1 | Issue 3

In what clinical scenarios might I consider performing TDM?

Peter L. Lakatos, MD

Volume 1 | Issue 4

When should I not use TDM?

Peter L. Lakatos, MD

Volume 1 | Issue 5

When in relation to the TNF-α antagonist’s dose should I perform TDM?

Peter L. Lakatos, MD

Volume 1 | Issue 6

In the presence of loss of response, can you help me interpret TDM results?

Shomron Ben-Horin, MD

Volume 1 | Issue 7

In the presence of loss of response, what should I do if my patient has a high infliximab level?

Simon PL. Travis, MD

Volume 1 | Issue 9

In the presence of loss of response, if I change the dose of infliximab, should I repeat TDM? If so, when?

Richard N. Fedorak, MD

Volume 1 | Issue 10

In the presence of loss of response, what should I do if my patient has a low infliximab level?

Peter L. Lakatos, MD

Volume 1 | Issue 8

In the presence of loss of response, what is the advantage of TDM to the healthcare provider?

Niels Vande Casteele, PharmD PhD

Volume 1 | Issue 11

In the presence of loss of response, what is the advantage of TDM to the patient?

A. Hillary Steinhart, MD

Volume 1 | Issue 12